Population-based screening for celiac disease reveals that the majority of patients are undiagnosed and improve on a gluten-free diet

Jan-Magnus Kvamme, Sveinung Sørbye, Jon Florholmen, Trond S Halstensen, Jan-Magnus Kvamme, Sveinung Sørbye, Jon Florholmen, Trond S Halstensen

Abstract

The impact of a gluten-free diet (GFD) on screen-detected celiac disease (CD) is currently ambiguous. We aimed to identify the population-based prevalence of undiagnosed adult CD and examine the impact of a GFD on screen-detected CD. In total, 12,981 adults participated in a population-based health study in Tromsø, Norway. Participants with increased levels of anti-tissue transglutaminase-2 IgA or anti-deamidated gliadin peptide IgG were invited to undergo gastroduodenoscopy with both histological and immunohistochemical examination of small-bowel biopsies. The prevalence of previously diagnosed CD was 0.37%. Additionally, the prevalence of previously undiagnosed CD was 1.10%. Thus, 1.47% of the population had CD, of whom 75% were previously undiagnosed. A GFD resulted in significant improvements in overall gastrointestinal symptoms, diarrhea, and health-related quality of life, with reduced abdominal discomfort (76%) and improved levels of energy (58%). The large majority of patients with adult CD were undiagnosed and benefited from a GFD with reduced gastrointestinal symptoms and improved health-related quality of life. In clinical practice, there should be a low threshold for CD testing even in the absence of abdominal complaints because most adult patients appear to consider their symptoms a part of their normal state and therefore remain untested and undiagnosed.Trial registration: Clinical Trials. Gov Identifier: NCT01695681.

Conflict of interest statement

Trond S. Halstensen has served as speaker, consultant, and head of the scientific board of the Norwegian Celiac Disease association. He has also served as a speaker for Phadia. Jan-Magnus Kvamme has served as a speaker for the Norwegian Celiac Disease association. Jon Florholmen and Sveinung W Sørbye declare no personal interests.

© 2022. The Author(s).

Figures

Figure 1
Figure 1
Flowchart of the study. CD celiac disease, TG2-IgA tissue transglutaminase 2-IgA antibodies, DGP-IgG deamidated gliadin peptide-IgG antibodies.
Figure 2
Figure 2
Serum TG2-IgA titers in participants with and without a biopsy-verified diagnosis. Serum TG2-IgA levels in participants with a biopsy-verified diagnosis (left panel, n = 173) had a similar distribution to those in participants who were not biopsied (right panel, n = 103, light-blue rhombi). The horizontal line indicates median TG2-IgA titers (U/mL). TG2-IgA tissue transglutaminase 2-IgA antibodies.
Figure 3
Figure 3
Distribution of serum DGP-IgG and TG2-IgA according to celiac disease status. Serum DGP-IgG (x-axis) and TG2-IgA (y-axis) from the participants (n = 173) with a biopsy-verified diagnosis. Although the DGP-IgG and TG2-IgA titers were significantly correlated in CD patients (p DGP-IgG deamidated gliadin peptide-IgG antibodies, TG2-IgA tissue transglutaminase 2-IgA antibodies, n number of participants.
Figure 4
Figure 4
Differences in gastrointestinal symptoms and health-related quality of life on a GFD. Score differences in individuals with a biopsy-proven CD (n = 79) between inclusion and follow-up on a GFD. The direction of change in the GSRS has been reversed. GSRS Gastrointestinal Symptoms Rating Scale, PGWB Psychological General Well-Being.
Figure 5
Figure 5
Self-reported changes (%) in symptoms at follow-up on a GFD. n = 78 (one missing), p 2 test).

References

    1. Green PHR, Cellier C. Celiac disease. N. Engl. J. Med. 2007;357:1731–1743. doi: 10.1056/NEJMra071600.
    1. Fuchs V, et al. Factors associated with long diagnostic delay in celiac disease. Scand. J. Gastroenterol. 2014;49:1304–1310. doi: 10.3109/00365521.2014.923502.
    1. Singh P, et al. Global prevalence of celiac disease: Systematic review and meta-analysis. Clin. Gastroenterol. Hepatol. 2018;16:823–836.e2. doi: 10.1016/j.cgh.2017.06.037.
    1. Vilppula A, et al. Increasing prevalence and high incidence of celiac disease in elderly people: A population-based study. BMC Gastroenterol. 2009;9:1–5. doi: 10.1186/1471-230X-9-49.
    1. Fluge G, Dybdahl JH, Ek J, Løvik A, Røhme R. Guidelines for diagnosis and follow-up of patients with celiac disease. Tidsskr Nor Lægeforen. 1997;117:672–674.
    1. Diez-Sampedro, A., Olenick, M., Maltseva, T. & Flowers, M. A gluten-free diet, not an appropriate choice without a medical diagnosis. J. Nutr. Metab.2019 (2019).
    1. Halstensen TS, Scott H, Brandtzaeg P. Intraepithelial T cells of the TCRγ/δ CD8− and Vδ1/Jδ1 phenotypes are increased in coeliac disease. Scand. J. Immunol. 1989;30:665–672. doi: 10.1111/j.1365-3083.1989.tb02474.x.
    1. Popp A, et al. A new intraepithelial γδ T-lymphocyte marker for celiac disease classification in formalin-fixed paraffin-embedded (FFPE) duodenal biopsies. Dig. Dis. Sci. 2021;66:3352–3358. doi: 10.1007/s10620-020-06680-x.
    1. Salmi TT, et al. Endomysial antibody-negative coeliac disease: Clinical characteristics and intestinal autoantibody deposits. Gut. 2006;55:1746–1753. doi: 10.1136/gut.2005.071514.
    1. Viljamaa M, et al. Is coeliac disease screening in risk groups justified? A fourteen-year follow-up with special focus on compliance and quality of life. Aliment. Pharmacol. Ther. 2005;22:317–324. doi: 10.1111/j.1365-2036.2005.02574.x.
    1. Mustalahti K, Collin P, Sievänen H, Salmi J, Mäki M. Osteopenia in patients with clinically silent coeliac disease warrants screening. Lancet. 1999;354:744–745. doi: 10.1016/S0140-6736(99)01990-X.
    1. Kurppa K, et al. Benefits of a gluten-free diet for asymptomatic patients with serologic markers of celiac disease. Gastroenterology. 2014;147:610–617. doi: 10.1053/j.gastro.2014.05.003.
    1. Vermeersch P, et al. Diagnostic performance of IgG anti-deamidated gliadin peptide antibody assays is comparable to IgA anti-tTG in celiac disease. Clin. Chim. Acta. 2010;411:931–935. doi: 10.1016/j.cca.2010.02.060.
    1. Ress K, et al. High prevalence of coeliac disease: Need for increasing awareness among physicians. Dig. Liver Dis. 2007;39:136–139. doi: 10.1016/j.dld.2006.07.012.
    1. Lindberg, M., Garmo Hov, G., Hardang, I. & Bjørke Monsen, A.-L. National User Handbook in Medical Biochemistry.
    1. Ludvigsson JF, et al. Outcome measures in coeliac disease trials: The Tampere recommendations. Gut. 2018;67:1410–1424. doi: 10.1136/gutjnl-2017-314853.
    1. Oxentenko AS, Murray JA. Celiac disease: Ten things that every gastroenterologist should know. Clin. Gastroenterol. Hepatol. 2015;13:1396–1404. doi: 10.1016/j.cgh.2014.07.024.
    1. Koskinen O, et al. Usefulness of small-bowel mucosal transglutaminase-2 specific autoantibody deposits in the diagnosis and follow-up of celiac disease. J. Clin. Gastroenterol. 2009;44:483–488. doi: 10.1097/MCG.0b013e3181b64557.
    1. Dickson BC, Streutker CJ, Chetty R. Coeliac disease: An update for pathologists. J. Clin. Pathol. 2006;59:1008–1061. doi: 10.1136/jcp.2005.035345.
    1. Hayat M, Cairns A, Dixon MF, O’Mahony S. Quantitation of intraepithelial lymphocytes in human duodenum: What is normal? J. Clin. Pathol. 2002;55:393–395. doi: 10.1136/jcp.55.5.393.
    1. Rubio-Tapia A, Hill ID, Kelly CP, Calderwood AH, Murray JA. ACG clinical guidelines: Diagnosis and management of celiac disease. Am. J. Gastroenterol. 2013;108:656–676. doi: 10.1038/ajg.2013.79.
    1. Rostami K, et al. ROC-king onwards: Intraepithelial lymphocyte counts, distribution and role in coeliac disease mucosal interpretation. Gut. 2017;66:2080–2086. doi: 10.1136/gutjnl-2017-314297.
    1. Spencer J, Isaacson PG, MacDonald TT, Thomas AJ, Walker-Smith JA. Gamma/delta T cells and the diagnosis of coeliac disease. Clin. Exp. Immunol. 2008;85:109–113. doi: 10.1111/j.1365-2249.1991.tb05690.x.
    1. Ludvigsson JF, et al. The Oslo definitions for coeliac disease and related terms. Gut. 2013;62:43–52. doi: 10.1136/gutjnl-2011-301346.
    1. Kurppa K, Collin P, Maaki M, Kaukinen K. Celiac disease and health-related quality of life. Expert Rev. Gastroenterol. Hepatol. 2011;5:83–90. doi: 10.1586/egh.10.81.
    1. Olafsson S, Hatlebakk JG, Berstad A. Patients with endoscopic gastritis and/or duodenitis improve markedly following eradication of Helicobacter pylori, although less so than patients with ulcers. Scand. J. Gastroenterol. 2002;37:1386–1394. doi: 10.1080/003655202762671251.
    1. Svedlund J, Sjödin I, Dotevall G. GSRS—A clinical rating scale for gastrointestinal symptoms in patients with irritable bowel syndrome and peptic ulcer disease. Dig. Dis. Sci. 1988;33:129–134. doi: 10.1007/BF01535722.
    1. Helvik AS, Jacobsen G, Hallberg LR. Psychological well-being of adults with acquired hearing impairment. Disabil. Rehabil. 2006;28:535–545. doi: 10.1080/09638280500215891.
    1. Dupuy, H. The Psychological General Well-Being (PGWB) index. in Assessment of Quality of Life in Clinical Trials of Cardiovascular Therapies 170–183 (Le Jacq Publishing, 1984).
    1. Husby S, et al. European Society for Pediatric Gastroenterology, Hepatology, and Nutrition Guidelines for the Diagnosis of Coeliac Disease. J. Pediatr. Gastroenterol. Nutr. 2012;54:136–160. doi: 10.1097/MPG.0b013e31821a23d0.
    1. Caio G, et al. Celiac disease: A comprehensive current review. BMC Med. 2019;17:1–20. doi: 10.1186/s12916-019-1380-z.
    1. Mustalahti K, et al. The prevalence of celiac disease in Europe: Results of a centralized, international mass screening project. Ann. Med. 2010;42:587–595. doi: 10.3109/07853890.2010.505931.
    1. Nachman F, et al. Quality of life in celiac disease patients: Prospective analysis on the importance of clinical severity at diagnosis and the impact of treatment. Dig. Liver Dis. 2009;41:15–25. doi: 10.1016/j.dld.2008.05.011.
    1. Nachman F, et al. Long-term deterioration of quality of life in adult patients with celiac disease is associated with treatment noncompliance. Dig. Liver Dis. 2010;42:685–691. doi: 10.1016/j.dld.2010.03.004.
    1. Lebwohl B, Rubio-Tapia A. Epidemiology, presentation, and diagnosis of celiac disease. Gastroenterology. 2021;160:63–75. doi: 10.1053/j.gastro.2020.06.098.
    1. Hujoel IA, et al. Natural history and clinical detection of undiagnosed coeliac disease in a North American community. Aliment. Pharmacol. Ther. 2018;47:1358–1366. doi: 10.1111/apt.14625.
    1. Kårhus LL, et al. Symptoms and biomarkers associated with undiagnosed celiac seropositivity. BMC Gastroenterol. 2021;21:90. doi: 10.1186/s12876-021-01667-y.
    1. Katz KD, et al. Screening for celiac disease in a North American population: Sequential serology and gastrointestinal symptoms. Am. J. Gastroenterol. 2011;106:133–139.
    1. van der Windt DAWM, Jellema P, Mulder CJ, Kneepkens CMF, van der Horst HE. Diagnostic testing for celiac disease among patients with abdominal symptoms. JAMA. 2010;303:1738–1746. doi: 10.1001/jama.2010.549.
    1. Mariné M, et al. Impact of mass screening for gluten-sensitive enteropathy in working population. World J. Gastroenterol. 2009;15:1331–1338. doi: 10.3748/wjg.15.1331.
    1. Ludvigsson JF, et al. Screening for celiac disease in the general population and in high-risk groups. United Eur. Gastroenterol. J. 2015;3:106–120. doi: 10.1177/2050640614561668.
    1. Stull DE, Leidy NK, Parasuraman B, Chassany O. Optimal recall periods for patient-reported outcomes: Challenges and potential solutions. Curr. Med. Res. Opin. 2009;25:929–942. doi: 10.1185/03007990902774765.
    1. Freeman HJ. Dietary compliance in celiac disease. World J. Gastroenterol. 2017;23:2635–2639. doi: 10.3748/wjg.v23.i15.2635.
    1. Kurppa K, et al. Factors associated with dietary adherence in celiac disease: A nationwide study. Digestion. 2012;86:309–314. doi: 10.1159/000341416.
    1. Ivarsson A, et al. High prevalence of undiagnosed coeliac disease in adults: A Swedish population-based study. J. Intern. Med. 1999;245:63–68. doi: 10.1046/j.1365-2796.1999.00403.x.
    1. Choung RS, et al. Prevalence and morbidity of undiagnosed celiac disease from a community-based study. Gastroenterology. 2017;152:830–839. doi: 10.1053/j.gastro.2016.11.043.
    1. Gould MJ, Brill H, Marcon MA, Munn NJ, Walsh CM. In screening for celiac disease, deamidated gliadin rarely predicts disease when tissue transglutaminase is normal. J. Pediatr. Gastroenterol. Nutr. 2019;68:20–25. doi: 10.1097/MPG.0000000000002109.
    1. Sollid LM. The roles of MHC class II genes and post-translational modification in celiac disease. Immunogenetics. 2017;69:605–616. doi: 10.1007/s00251-017-0985-7.
    1. Lande A, et al. HLA -A, -C, -B, -DRB1, -DQB1 and -DPB1 allele and haplotype frequencies in 4514 healthy Norwegians. Hum. Immunol. 2018;79:527–529. doi: 10.1016/j.humimm.2018.04.012.
    1. Husby S, Murray JA, Katzka DA. AGA clinical practice update on diagnosis and monitoring of celiac disease—Changing utility of serology and histologic measures: Expert review. Gastroenterology. 2019;156:885–889. doi: 10.1053/j.gastro.2018.12.010.
    1. Biesiekierski JR, et al. Gluten causes gastrointestinal symptoms in subjects without celiac disease: A double-blind randomized placebo-controlled trial. Am. J. Gastroenterol. 2011;106:508–514. doi: 10.1038/ajg.2010.487.
    1. Laurikka P, et al. Gastrointestinal symptoms in celiac disease patients on a long-term gluten-free diet. Nutrients. 2016;8:429. doi: 10.3390/nu8070429.
    1. Hære P, et al. Long-term mucosal recovery and healing in celiac disease is the rule—Not the exception. Scand. J. Gastroenterol. 2016;51:1439–1446. doi: 10.1080/00365521.2016.1218540.
    1. Chou R, et al. Screening for celiac disease: Evidence report and systematic review for the US Preventive Services Task Force. JAMA. 2017;317:1258–1268. doi: 10.1001/jama.2016.10395.
    1. Popp, A., Kivelä, L., Fuchs, V. & Kurppa, K. Diagnosing celiac disease: Towards wide-scale screening and serology-based criteria? Gastroenterol. Res. Pract.2019 (2019).
    1. Kivelä L, et al. Long-term health and treatment outcomes in adult coeliac disease patients diagnosed by screening in childhood. United Eur. Gastroenterol. J. 2018;6:1022–1031. doi: 10.1177/2050640618778386.
    1. Paavola A, et al. Gastrointestinal symptoms and quality of life in screen-detected celiac disease. Dig. Liver Dis. 2012;44:814–818. doi: 10.1016/j.dld.2012.04.019.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다